Actionable news
0
All posts from Actionable news
Actionable news in AGN: ALLERGAN Inc,

Evidence Pfizer Could Revisit GlaxoSmithKline Or AstraZeneca Deals If Allergan Falls Through

Invest with Confidence. Are you a financial professional? Stay on top of your portfolio with Benzinga Pro's real-time newsfeed and alerts and never miss a headline again.
Don't miss the chance to try it FREE today.

Despite the proposed merger agreement with Allergan plc Ordinary Shares AGN 16.45%, analysts have been talking about other potential moves Pfizer Inc. PFE 2.15% could engage in if the deal were to fall through.

Based upon the imbalance between the proposed merger pricing of Allergan (at an implied $333.24/share), and the current trading price of Allergan ($232 Tuesday afternoon), analysts have observed a substantial risk that the deal will not come to fruition after all.

Analysts Look To Other Names In The Space

Analysts at Jefferies and Bernstein have both offered up GlaxoSmithKline...


More